The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

AbbVie has reported that the Phase III TEMPO-2 trial of tavapadon for early-stage Parkinson's disease met its primary endpoint.

With an accuracy of 86%, the biomarker panel has the potential to be clinically useful in diagnosis, management, and ...

The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some ...

CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...

US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ovarian cancer.

With this year's ANNEXA-I trial, manufacturer AstraZeneca was able to fulfill the FDA's request for a randomized controlled trial of andexanet with a clinical endpoint. The trial showed that the ...

Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a ...

The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75 ...

Q32 Bio (QTTB) announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart, or ADX-914, which ...

Acelyrin (SLRN) announced that its Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of a ...